Prescription profile of antiarrhythmic drugs in a group of patients in Colombia

A. Gaviria-Mendoza, L. Chica-Quintero, Paula Córtes-Avila, Viviana Poveda-Hurtado, J. Machado-Alba
{"title":"Prescription profile of antiarrhythmic drugs in a group of patients in Colombia","authors":"A. Gaviria-Mendoza, L. Chica-Quintero, Paula Córtes-Avila, Viviana Poveda-Hurtado, J. Machado-Alba","doi":"10.21615/cesmedicina.5308","DOIUrl":null,"url":null,"abstract":"Objective: To determine the prescription patterns of antiarrhythmic drugs and variables associated with their use in a population of patients affiliated with the Colombian Health System. Methods: A cross-sectional study was performed on a population database with patients who received antiarrhythmics from March to May 2016. Sociodemographic, pharmacological and comedication variables were included. SPSS-24 was used for data analysis using X2 tests and multivariate analyses. Results: In total, 2772 patients were treated with antiarrhythmics in the evaluated period. The mean age was 70.1 ± 13.1 years, and 51.2% were women. In total, 79.4% used a β-blocker, 58.5% amiodarone and 2.9% a calcium channel blocker. Moreover, 1192 (43.0%) patients were prescribed a single antiarrhythmic, and 1580 (57.0%) received two or more. There were 2603 patients (93.9%) with comedication, including lipid-lowering drugs (62.6%), inhibitors of the renin angiotensin aldosterone system (62.6%) and antiplatelet drugs (42.0%). Age older than 65 years increased the probability of comedication (odds ratio [OR]: 2.48; 95% confidence interval [95% CI]: 1.59-3.85), and the risk was proportional to age. We identified 1364 patients treated with conditional risk medications for QT prolongation (49.2%), 68 with a possible risk (2.5%) and 171 (6.2%) with a known risk. Conclusion: Antiarrhythmic drugs recommended by clinical practice guidelines are mainly used; however, risk interactions of QT prolongation were identified and should be taken into account by physicians to avoid adverse events or complications.","PeriodicalId":9722,"journal":{"name":"CES Medicina Veterinaria y Zootecnia","volume":"1 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-10-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"CES Medicina Veterinaria y Zootecnia","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.21615/cesmedicina.5308","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 1

Abstract

Objective: To determine the prescription patterns of antiarrhythmic drugs and variables associated with their use in a population of patients affiliated with the Colombian Health System. Methods: A cross-sectional study was performed on a population database with patients who received antiarrhythmics from March to May 2016. Sociodemographic, pharmacological and comedication variables were included. SPSS-24 was used for data analysis using X2 tests and multivariate analyses. Results: In total, 2772 patients were treated with antiarrhythmics in the evaluated period. The mean age was 70.1 ± 13.1 years, and 51.2% were women. In total, 79.4% used a β-blocker, 58.5% amiodarone and 2.9% a calcium channel blocker. Moreover, 1192 (43.0%) patients were prescribed a single antiarrhythmic, and 1580 (57.0%) received two or more. There were 2603 patients (93.9%) with comedication, including lipid-lowering drugs (62.6%), inhibitors of the renin angiotensin aldosterone system (62.6%) and antiplatelet drugs (42.0%). Age older than 65 years increased the probability of comedication (odds ratio [OR]: 2.48; 95% confidence interval [95% CI]: 1.59-3.85), and the risk was proportional to age. We identified 1364 patients treated with conditional risk medications for QT prolongation (49.2%), 68 with a possible risk (2.5%) and 171 (6.2%) with a known risk. Conclusion: Antiarrhythmic drugs recommended by clinical practice guidelines are mainly used; however, risk interactions of QT prolongation were identified and should be taken into account by physicians to avoid adverse events or complications.
哥伦比亚一组患者抗心律失常药物的处方分析
目的:确定抗心律失常药物的处方模式及其在哥伦比亚卫生系统附属患者群体中使用的相关变量。方法:对2016年3月至5月接受抗心律失常药物治疗的人群数据库进行横断面研究。包括社会人口学、药理学和药物变量。采用SPSS-24进行X2检验和多因素分析。结果:共2772例患者在评估期内接受了抗心律失常药物治疗。平均年龄70.1±13.1岁,女性占51.2%。总的来说,79.4%的人使用β受体阻滞剂,58.5%的人使用胺碘酮,2.9%的人使用钙通道阻滞剂。此外,1192例(43.0%)患者服用单一抗心律失常药物,1580例(57.0%)患者服用两种或两种以上抗心律失常药物。2603例(93.9%)患者接受了药物治疗,包括降脂药物(62.6%)、肾素血管紧张素醛固酮系统抑制剂(62.6%)和抗血小板药物(42.0%)。年龄大于65岁增加服药的概率(优势比[OR]: 2.48;95%可信区间[95% CI]: 1.59-3.85),且风险与年龄成正比。我们确定了1364例接受有条件风险药物治疗的QT延长患者(49.2%),68例可能存在风险(2.5%),171例已知风险(6.2%)。结论:以临床实践指南推荐的抗心律失常药物为主;然而,QT间期延长的风险相互作用已被确定,医生应考虑到这一点,以避免不良事件或并发症。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信